Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of alirocumab in heterozygous familial hypercholesterolemia
2013-002572-40Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alirocumab in familial hypercholesterolemia (FH), sponsored by Sanofi. Primary endpoint: Safety parameters. Started Oct 2013; status: completed.
02
Drugs
alirocumab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on 2013-002572-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002572-40.